FDA “Approvable” Letter For Gestiva Recommends Additional Animal Study
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, Adeza’s long-acting form of progesterone would be the first FDA-approved treatment for preterm birth.
You may also be interested in...
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
Columbia Labs' Prochieve Could Address $150 Million To $300 Million Preterm Birth Market
Firm anticipates sNDA approval for progesterone vaginal gel product in recurrent preterm birth as early as 2008.